What is ACCURE Therapeutics?
Headquartered in Barcelona, ACCURE Therapeutics is a specialized translational neuroscience R&D enterprise focused on the discovery and development of innovative drugs for serious CNS conditions. Since its inception in 2020, the company has cultivated a unique portfolio targeting optic neuritis, multiple sclerosis, Parkinson's disease, and epilepsy. Unlike traditional pharmaceutical entities, ACCURE employs a flexible, science-agnostic methodology that allows for the rapid evaluation and advancement of new chemical entities. This strategic agility, combined with an experienced leadership team, positions the company as a high-potential player in the global neuro-therapeutic market, bridging the gap between early-stage academic discovery and clinical-grade pharmaceutical development.
How much funding has ACCURE Therapeutics raised?
ACCURE Therapeutics has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2025): $1.6M with participation from The FNR and The Michael J Fox Foundation
Key Investors in ACCURE Therapeutics
The FNR
The Luxembourg National Research Fund acts as a primary public funding body, supporting high-impact scientific research and fostering international collaboration across health and technology sectors.
The Michael J Fox Foundation
A leading non-profit organization dedicated to accelerating the development of improved therapies and a cure for Parkinson's disease through strategic research grants and advocacy.
What's next for ACCURE Therapeutics?
With the recent influx of capital, ACCURE Therapeutics is poised to scale its R&D operations and deepen its clinical pipeline. The strategic roadmap focuses on advancing its proprietary chemical entities toward human clinical trials, with a specific emphasis on neuro-regeneration and neuro-protection. As the company matures, it is expected to seek further collaborative partnerships with global pharmaceutical leaders to facilitate the commercialization of its CNS assets. The focus remains on maintaining a lean, high-impact operational model that maximizes the probability of success for its disease-modifying candidates, ultimately aiming to transform the standard of care for patients suffering from chronic neurological diseases.
See full ACCURE Therapeutics company page
